Evidence map›Paper›PMID 24681957›Full record

ArticleOncogene2015

The Parkinson's gene PINK1 regulates cell cycle progression and promotes cancer-associated phenotypes.

C H O'Flanagan, V A Morais, W Wurst, B De Strooper, C O'Neill

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. PINK1 regulates apoptosis of osteosarcoma as the target gene of cisplatin.Journal of orthopaedic surgery and research · 2023
    Article
  13. Review
  14. Article
  15. Review
  16. Experimental biology and medicine (Maywood, N.J.) · 2022
    Article
  17. PARK2 regulates eIF4B-driven lymphomagenesis.Molecular cancer research : MCR · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

C H O'FlanaganSchool of Biochemistry and Cell Biology, BioSciences Institute, University College Cork, Cork, Ireland.
V A Morais1] VIB Center for the Biology of Disease, VIB, Leuven, Belgium [2] Center for Human Genetics and LIND, KU Leuven, Leuven, Belgium.
W Wurst1] Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Developmental Genetics, München-Neuherberg, Germany [2] Technische Universität München-Weihenstephan, Lehrstuhl für Entwicklungsgenetik, c/o Helmholtz Zentrum München, München-Neuherberg, Germany [3] German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
B De Strooper1] VIB Center for the Biology of Disease, VIB, Leuven, Belgium [2] Center for Human Genetics and LIND, KU Leuven, Leuven, Belgium [3] UCL Institute of Neurology, London, UK.
C O'NeillSchool of Biochemistry and Cell Biology, BioSciences Institute, University College Cork, Cork, Ireland.
University College Cork · IEVIB-KU Leuven Center for Cancer Biology · BEHelmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PINK1 (phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-induced kinase 1), a Parkinson's disease-associated gene, was identified originally because of its induction by the tumor-suppressor PTEN. PINK1 promotes cell survival and potentially metastatic functions and protects against cell stressors including chemotherapeutic agents. However, the mechanisms underlying PINK1 function in cancer cell biology are unclear. Here, using several model systems, we show that PINK1 deletion significantly reduced cancer-associated phenotypes including cell proliferation, colony formation and invasiveness, which were restored by human PINK1 overexpression. Results show that PINK1 deletion causes major defects in cell cycle progression in immortalized mouse embryonic fibroblasts (MEFs) from PINK1(-/-) mice, and in BE(2)-M17 cells stably transduced with short hairpin RNA against PINK1. Detailed cell cycle analyses of MEF cell lines from several PINK1(-/-) mice demonstrate an increased proportion of cells in G2/M and decreased number of cells in G1 following release from nocodazole block. This was concomitant with increased double and multi-nucleated cells, a reduced ability to undergo cytokinesis and to re-enter G1, and significant alterations in cell cycle markers, including failure to increase cyclin D1, all indicative of mitotic arrest. PINK1(-/-) cells also demonstrated ineffective cell cycle exit following serum deprivation. Cell cycle defects associated with PINK1 deficiency occur at points critical for cell division, growth and stress resistance in cancer cells were rescued by ectopic expression of human PINK1 and demonstrated PINK1 kinase dependence. The importance of PINK1 for cell cycle control is further supported by results showing that cell cycle deficits induced by PINK1 deletion were linked mechanistically to aberrant mitochondrial fission and its regulation by dynamin-related protein-1 (Drp1), known to be critical for progression of mitosis. Our data indicate that PINK1 has tumor-promoting properties and demonstrates a new function for PINK1 as a regulator of the cell cycle.

Indexed as

AnimalsCell DivisionCell Line, TumorCell MovementCell ProliferationCyclin D1CytokinesisDynaminsGene Expression Regulation, NeoplasticGTP PhosphohydrolasesHeLa CellsHumansMCF-7 CellsMiceMice, KnockoutMicrotubule-Associated ProteinsCCND1 protein, humanCyclin D1DNM1L protein, humanDynaminsGTP PhosphohydrolasesMicrotubule-Associated ProteinsMitochondrial ProteinsProtein KinasesPTEN-Induced Putative KinaseRNA, Small Interfering

Identifiers

PMID24681957
OpenAlexW2090963058

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.